Edition:
United Kingdom

Onconova Therapeutics Inc (ONTX.OQ)

ONTX.OQ on NASDAQ Stock Exchange Capital Market

2.35USD
23 Aug 2019
Change (% chg)

$0.11 (+4.91%)
Prev Close
$2.24
Open
$2.22
Day's High
$2.35
Day's Low
$2.20
Volume
2,358
Avg. Vol
7,394
52-wk High
$11.17
52-wk Low
$1.71

Latest Key Developments (Source: Significant Developments)

Onconova Therapeutics Qtrly Net Loss Per Share $0.60
Wednesday, 14 Aug 2019 

Aug 14 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS, INC. REPORTS BUSINESS HIGHLIGHTS AND SECOND QUARTER 2019 FINANCIAL RESULTS.QTRLY NET LOSS PER SHARE $0.60.QTRLY REVENUE $2 MILLION VERSUS $ 485,000 YEAR AGO.CASH AND CASH EQUIVALENTS AS OF JUNE 30, 2019, TOTALED $5.9 MILLION COMPARED TO $17.0 MILLION AT DECEMBER 31, 2018.  Full Article

Onconova Therapeutics, Inc. Reports Business Highlights And First Quarter 2019 Financial Results
Tuesday, 14 May 2019 

May 14 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS, INC. REPORTS BUSINESS HIGHLIGHTS AND FIRST QUARTER 2019 FINANCIAL RESULTS.ONCONOVA THERAPEUTICS INC QUARTERLY LOSS PER SHARE $1.29.ONCONOVA THERAPEUTICS INC - CDK 4/6 INHIBITOR IS EXPECTED TO ENTER A PHASE 1 CLINICAL TRIAL IN U.S. DURING SECOND HALF OF 2019..ONCONOVA THERAPEUTICS INC - CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2019, TOTALED $10.4 MILLION COMPARED TO $17.0 MILLION AT DECEMBER 31, 2018..  Full Article

Onconova Therapeutics Expects Cash, Cash Equivalents Will Be Sufficient To Fund Ongoing Trials, Operations Into Q4 2019
Tuesday, 26 Mar 2019 

March 26 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS, INC. REPORTS BUSINESS HIGHLIGHTS AND FULL YEAR 2018 FINANCIAL RESULTS.ONCONOVA THERAPEUTICS - EXPECTS THAT CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND ONGOING TRIALS AND OPERATIONS INTO Q4 2019.  Full Article

Onconova Therapeutics Reports Qtrly Loss Per Share $0.07
Tuesday, 14 Aug 2018 

Aug 14 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS REPORTS BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR SECOND QUARTER 2018.ONCONOVA THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.07.ONCONOVA THERAPEUTICS INC - QTRLY REVENUE $485,000 VERSUS $324,000.  Full Article

Onconova Therapeutics Reports Full-Year 2017 Results
Thursday, 8 Mar 2018 

March 8 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS, INC. REPORTS BUSINESS HIGHLIGHTS AND FULL YEAR 2017 FINANCIAL RESULTS.ONCONOVA THERAPEUTICS INC - CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2017, TOTALED $4.0 MILLION, COMPARED TO $21.4 MILLION AS OF DECEMBER 31, 2016.ONCONOVA THERAPEUTICS - EXPECTS CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND ONGOING TRIALS AND OPERATIONS INTO Q3 2018.  Full Article

Onconova Therapeutics Announces License Agreement With Pint Pharma To Commercialize Rigosertib
Monday, 5 Mar 2018 

March 5 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH PINT PHARMA TO COMMERCIALIZE RIGOSERTIB FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES IN LATIN AMERICA.ONCONOVA THERAPEUTICS INC - ONCONOVA ALSO ELIGIBLE TO RECEIVE UP TO $42.75 MILLION IN REGULATORY AND SALES MILESTONES.ONCONOVA THERAPEUTICS - IN EXCHANGE FOR RIGHTS, PINT WILL MAKE INVESTMENT TOTALING UP TO $2.5 MILLION BY PURCHASING SHARES AT A PREMIUM TO MARKET.ONCONOVA THERAPEUTICS INC - RIGOSERTIB TOP-LINE DATA EXPECTED IN 2019.  Full Article

683 Capital Management Reports 21.8 Pct Stake In Onconova Therapeutics
Friday, 16 Feb 2018 

Feb 16 (Reuters) - Onconova Therapeutics Inc ::683 CAPITAL MANAGEMENT LLC REPORTS 21.8 PERCENT STAKE IN ONCONOVA THERAPEUTICS INC AS OF FEB 8 - SEC FILING.683 CAPITAL MANAGEMENT LLC SAYS PURCHASED SECURITIES OF ONCONOVA THERAPEUTICS BASED ON BELIEF THAT SUCH SECURITIES, WHEN PURCHASED, WERE "UNDERVALUED".  Full Article

Onconova Therapeutics Says Entered Into Cooperative Research And Development Agreement With NCI
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS SAYS ENTERED INTO COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH NATIONAL CANCER INSTITUTE.ONCONOVA THERAPEUTICS - UNDER TERMS, NCI WILL CONDUCT RESEARCH ON RIGOSERTIB IN PEDIATRIC CANCER ASSOCIATED RASOPATHIES.  Full Article

Onconova Therapeutics Announces License And Collaborative Development Agreement With Hanx Biopharma
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS ANNOUNCES LICENSE AND COLLABORATIVE DEVELOPMENT AGREEMENT WITH HANX BIOPHARMACEUTICALS FOR ON 123300, A DUAL INHIBITOR OF CDK4/6 + ARK5.ONCONOVA THERAPEUTICS INC - HANX WILL FUND STUDIES TOWARDS INVESTIGATIONAL NEW DRUG APPLICATIONS IN BOTH U.S. AND CHINA.ONCONOVA THERAPEUTICS INC - AGREEMENT INCLUDES LICENSING FEE, CUSTOMARY MILESTONE PAYMENTS AND ROYALTIES ON SALES OF ON 123300.ONCONOVA THERAPEUTICS INC - HANX TO COMMERCIALIZE ON 123300 IN GREATER CHINA, ONCONOVA RETAINS RIGHTS IN REST OF WORLD.  Full Article

Onconova Therapeutics files for mixed shelf offering of upto $84.5 mln
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Onconova Therapeutics Inc ::Onconova Therapeutics Inc files for mixed shelf offering of upto $84.5 million- SEC filing‍​.  Full Article